WO1995025545A1 - Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux - Google Patents

Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux Download PDF

Info

Publication number
WO1995025545A1
WO1995025545A1 PCT/EP1995/000973 EP9500973W WO9525545A1 WO 1995025545 A1 WO1995025545 A1 WO 1995025545A1 EP 9500973 W EP9500973 W EP 9500973W WO 9525545 A1 WO9525545 A1 WO 9525545A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
combination
composition containing
dimeticone
dimethylpoly
Prior art date
Application number
PCT/EP1995/000973
Other languages
English (en)
Inventor
Alfred Schmidt
Hans-Jürgen Upmeyer
Original Assignee
Alfred Schmidt
Upmeyer Hans Juergen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfred Schmidt, Upmeyer Hans Juergen filed Critical Alfred Schmidt
Priority to CZ963007A priority Critical patent/CZ300796A3/cs
Priority to EP95913130A priority patent/EP0804242A1/fr
Priority to AU20714/95A priority patent/AU706351B2/en
Priority to US08/716,161 priority patent/US5834004A/en
Priority to JP7524363A priority patent/JPH09510466A/ja
Priority to CA002185883A priority patent/CA2185883C/fr
Priority to NZ282805A priority patent/NZ282805A/en
Priority to SK1324-96A priority patent/SK132496A3/sk
Publication of WO1995025545A1 publication Critical patent/WO1995025545A1/fr
Priority to NO963893A priority patent/NO963893L/no
Priority to FI963683A priority patent/FI963683A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • Dimeticone as a Transport and Carrier System and/or Drug Delivery System
  • the invention relates to dimethylpolysiloxane (dimeticone) to be used as a transport and carrier system and/or a drug delivery system for pharmaceutical drugs for instance for the treatment of gastro-intestinal diseases. Moreover, the invention relates to pharmaceutical compositions containing dimethylpolysiloxane as a transport and carrier system and/or as a drug delivery system in combination with an active ingredient and methods related thereto.
  • dimeticone-containing preparations are used to treat symptoms such as flatulence, sensation of repletion (bloating) and meteorism. Moreover, the use of dimeticone for treating inflammatory and ulcerous diseases of the esophagus, the stomach and the duodenum has been described.
  • the galenics of a pharmaceutical composition should be such that only the
  • the therapeutically active ingredient right at the site where it is to produce its effect or at the site where it is absorbed so as to increase the local bioavailability and/or general bioavailability of the active ingredient (for instance by averting a first pass effect in the liver) or so as to avoid systemic side effects as much as possible.
  • the continuous peristalsis, the variation of the chemical conditions over the length of the digestive tract, and the morphology of the surface of the GI tract are obstacles to a prolonged residence time in the different sections of the tract (such as the esophagus, stomach, duodenum, and colon) .
  • the present invention provides a carrier that lends itself for use in particular galenic pharmaceutical forms for oral, rectal and intraoperative applications which release and/or fix the active ingredient continuously at the very site where it is to produce its effect or is absorbed.
  • dimeticone because of its unique physico-chemical properties is ideally suited for such purposes.
  • Dimeticone has a very wide range of viscosities, depending on the degree of polymerization.
  • the viscosity of dimeticone to be used in accordance with the invention may vary, depending on the therapeutical purpose, the nature and location of the condition to be treated as well as the drug to be administered.
  • dimeticone having a kinematic viscosity in the range of 10 to 100,000 mm .S -1 is used.
  • dimeticone having a kinematic viscosity in the range of 300 to 1,500 mm .S "1 is particularly preferred. Dimeticone may also be supplemented with silicone dioxide as it is for example contained in the product Simeticone.
  • Dimeticone was found to show a particular association with or affinity to the surface structure of the GI tract. Because of an increased adhesion resulting from the adhesive properties of dimeticone, the residence time of an active ingredient in a region of the GI tract can be substantially prolonged if dimeticone is used as a transport or carrier system.
  • dimeticone because of the different chemical, morphological and physiological conditions along the GI tract, the affinity and association of dimeticone with the epithelial cells of the GI tract is not uniform. Thus, in order to optimize the effect of dimeticone as a transport and carrier system and/or drug delivery system for any particular drug at any particular site of the GI tract, dimeticone with the appropriate viscosity should be chosen, depending on the nature of the therapy and drug as well as the location in the GI tract. This may readily be determined' by experimentation.
  • dimeticone is not limited to the treatment of the GI tract. It may also be used in the treatment of the cardiovascular system the lungs, the brain and all hollow organs.
  • dimeticone was found to be particularly suitable as a transport and carrier system or a drug delivery system for cytostatic drugs, immunosup- pressants, immunomodulating and immunostimulative substances, biological response modifying (BRM) substances, radio-, chemo- and photosensitizers, anti-inflammatory substances, such as corticoids, antibiotics, analgesics, locally effective anestetics, antiphlogistics, non-steroidal antirheumatics, antiviral substances, bismuth preparations and motility inhibiting and motility enhancing substances.
  • BRM biological response modifying
  • dimeticone as a carrier for the photo- sensitizer ⁇ 5-amino levulinic acid (ALA) , the H-, antagonists (such as ranitidine and cimetidine) and the proton pump inhibitors (such as omeprazole and lansoprazole) is particularly preferred.
  • the pharmaceutical compositions which contain dimeticone in combination with one of the afore-mentioned substances therefore lend themselves particularly well for the treatment of inflammatory, infectious, ulcerous and neoplastic diseases of the GI tract.
  • the dimeticone-containing pharmaceutical composition may be formulated in an enteral form according to conventional methods in order to prevent dimeticone and the active ingredient from remaining in the upper zone of the GI tract.
  • the properties of the pharmaceutical composition should be so adjusted that it has an increased affinity for the lower part of the GI tract.
  • Direct application for instance via the bioptic channel of an endoscope, bronchoscope or proctoscope, intraoperative or by instillation, is particularly preferred.
  • the dimeticone-containing pharmaceutical composition should also contain highly dispersed silicon dioxide and/or a pharmaceutically acceptable surface-active agent.
  • the ratio of dimethylpolysiloxane to the surface-active agent is preferably 3 to 10 : 1, in particular 4 to 6 : 1, and the ratio of highly dispersed silicon dioxide to dimethylpolysiloxane is preferably 3 to 50% (wt/wt) .
  • a preferred range for the latter ratio is 30 to 40% (wt/wt) , the value of 35 to 36% being particularly preferred.
  • the concentration of the surface active agent is preferably at least 1.5 % (wt/wt).
  • a particularly preferred dimeticone formulation contains 8-10% (wt/wt) of the surface active agent.
  • Stearic salts or long chain alkanoic acids in particular C- j ⁇ -C- ⁇ g alkanoic acids, such as myristic acid, palmitic acid and stearic acid, and their salts, such as magnesium or calcium salts and mixtures thereof can be suitably used as pharmaceutically acceptable surface active agents.
  • ALA ⁇ -amino levulinic acid containing emulsion
  • colloidal magnesium aluminum silicate
  • the emulsion of the Example is intended for the photodynamic therapy of tumors of the GI tract, the emulsion being applied by means of an endoscope at the very site where the effect is to be elicited.

Abstract

L'invention se rapporte à du diméthylpolysiloxane (diméticone) destiné à être utilisé en tant que système véhiculaire et/ou d'apport médicamenteux. En outre, l'invention se rapporte à des compositions pharmaceutiques contenant du diméthylpolysiloxane en tant que système véhiculaire et/ou d'apport médicamenteux en association avec un principe actif.
PCT/EP1995/000973 1994-03-18 1995-03-15 Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux WO1995025545A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CZ963007A CZ300796A3 (en) 1994-03-18 1995-03-15 Use of dimeticon as transpot and supporting system and/or a medicament delivering system
EP95913130A EP0804242A1 (fr) 1994-03-18 1995-03-15 Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux
AU20714/95A AU706351B2 (en) 1994-03-18 1995-03-15 The use of dimeticone as a transport and carrier system and/or drug delivery system
US08/716,161 US5834004A (en) 1994-03-18 1995-03-15 Enteral composition comprising dimethicone and a photosensitizer and a method of delivery
JP7524363A JPH09510466A (ja) 1994-03-18 1995-03-15 運搬およびキャリアーシステムおよび／またはドラッグデリバリーシステムとしてのジメチコンの使用
CA002185883A CA2185883C (fr) 1994-03-18 1995-03-15 Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux
NZ282805A NZ282805A (en) 1994-03-18 1995-03-15 Use of dimethylpolysiloxane (dimeticone) as a carrier in medicaments
SK1324-96A SK132496A3 (en) 1994-03-18 1995-03-15 The use of dimeticone as a transport and carrier system and/or drug delivery system
NO963893A NO963893L (no) 1994-03-18 1996-09-17 Anvendelse av dimeticon som et transport- og bærersystem og/eller medikamentavleveringssystem
FI963683A FI963683A (fi) 1994-03-18 1996-09-17 Dimetikonin käyttö kuljetus- ja kantoainejärjestelmänä ja/tai lääkeaineen jakelujärjestelmä

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4409357.8 1994-03-18
DE4409357A DE4409357C2 (de) 1994-03-18 1994-03-18 Verwendung von Dimeticon zur Eradikation von Heliobacter pylori

Publications (1)

Publication Number Publication Date
WO1995025545A1 true WO1995025545A1 (fr) 1995-09-28

Family

ID=6513210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/000973 WO1995025545A1 (fr) 1994-03-18 1995-03-15 Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux

Country Status (14)

Country Link
EP (1) EP0804242A1 (fr)
JP (1) JPH09510466A (fr)
CN (1) CN1244129A (fr)
AU (1) AU699199B2 (fr)
CA (1) CA2185882A1 (fr)
CZ (1) CZ300796A3 (fr)
DE (1) DE4409357C2 (fr)
FI (1) FI963682A (fr)
HU (1) HU215595B (fr)
NO (1) NO963893L (fr)
NZ (1) NZ282805A (fr)
PL (1) PL316307A1 (fr)
SK (1) SK132496A3 (fr)
WO (1) WO1995025545A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012791A (es) * 2003-05-25 2006-02-22 Wang Yuwan Formulacion sostenida que contiene dimeticona.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3848M (fr) * 1964-05-04 1966-01-17 Robert Schapiro Associations thérapeutiques pour traitement de nombreux troubles digestifs organiques ou fonctionnels.
FR2110314A1 (fr) * 1970-10-09 1972-06-02 Angeli Inst Spa
EP0219076A2 (fr) * 1985-10-11 1987-04-22 Sumitomo Pharmaceuticals Company, Limited Composition à effet retardé
US4837029A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Low foaming, aqueously homogenizable rifampin composition
WO1991004034A1 (fr) * 1989-09-15 1991-04-04 Pehrom Pharmaceutical Corporation Preparation locale de traitement d'ulceres aphteux et d'autres lesions
EP0428296A2 (fr) * 1989-11-01 1991-05-22 McNEIL-PPC, INC. Compositions pharmaceutiques pour le traitement de problèmes gastro-intestinaux
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
WO1994003209A1 (fr) * 1992-07-29 1994-02-17 Merck & Co., Inc. Combinaisons dexibuprofene/antacide/simethicone
WO1995005813A1 (fr) * 1993-08-27 1995-03-02 Noven Pharmaceuticals, Inc. Compositions et procedes d'administration d'acide delta-aminolevulinique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406248B1 (fr) * 1989-01-19 1994-06-08 Alfred Schmidt Utilisation de dimethylpolysiloxane pour traiter les affections du tractus digestif

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3848M (fr) * 1964-05-04 1966-01-17 Robert Schapiro Associations thérapeutiques pour traitement de nombreux troubles digestifs organiques ou fonctionnels.
FR2110314A1 (fr) * 1970-10-09 1972-06-02 Angeli Inst Spa
EP0219076A2 (fr) * 1985-10-11 1987-04-22 Sumitomo Pharmaceuticals Company, Limited Composition à effet retardé
US4837029A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Low foaming, aqueously homogenizable rifampin composition
WO1991004034A1 (fr) * 1989-09-15 1991-04-04 Pehrom Pharmaceutical Corporation Preparation locale de traitement d'ulceres aphteux et d'autres lesions
EP0428296A2 (fr) * 1989-11-01 1991-05-22 McNEIL-PPC, INC. Compositions pharmaceutiques pour le traitement de problèmes gastro-intestinaux
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
WO1994003209A1 (fr) * 1992-07-29 1994-02-17 Merck & Co., Inc. Combinaisons dexibuprofene/antacide/simethicone
WO1995005813A1 (fr) * 1993-08-27 1995-03-02 Noven Pharmaceuticals, Inc. Compositions et procedes d'administration d'acide delta-aminolevulinique

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
EP1084706A2 (fr) * 1999-09-07 2001-03-21 McNEIL-PPC, INC. Utilisation de la simethicone dans le traitement de la colite ulcéreuse
EP1084706A3 (fr) * 1999-09-07 2002-07-17 McNEIL-PPC, INC. Utilisation de la simethicone dans le traitement de la colite ulcéreuse

Also Published As

Publication number Publication date
NZ282805A (en) 1998-02-26
FI963682A0 (fi) 1996-09-17
NO963893D0 (no) 1996-09-17
FI963682A (fi) 1996-11-13
HUT75711A (en) 1997-05-28
HU215595B (hu) 1999-01-28
AU699199B2 (en) 1998-11-26
PL316307A1 (en) 1997-01-06
SK132496A3 (en) 1997-06-04
AU2071395A (en) 1995-10-09
EP0804242A1 (fr) 1997-11-05
DE4409357A1 (de) 1995-09-21
JPH09510466A (ja) 1997-10-21
CN1244129A (zh) 2000-02-09
CZ300796A3 (en) 1997-09-17
DE4409357C2 (de) 1996-10-17
CA2185882A1 (fr) 1995-09-28
HU9602839D0 (en) 1996-12-30
NO963893L (no) 1996-11-04

Similar Documents

Publication Publication Date Title
JP3706792B2 (ja) 局所用亜鉛組成物および使用方法
AU745281B2 (en) Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis
JPS6261917A (ja) アリ−ルプロピオン酸誘導体の経皮的に吸収しうる含水製剤とその製造方法
RU2227033C2 (ru) Тауролидин и/или таурултам при лечении инфекционной язвенной болезни или инфекционного гастрита
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
US6689399B1 (en) Transdermal delivery of an anti-inflammatory composition
ES2259981T3 (es) Composicion laxante que contiene simeticona.
US5834004A (en) Enteral composition comprising dimethicone and a photosensitizer and a method of delivery
JP3895368B2 (ja) アフタおよび口内炎の治療におけるジメチコーンの使用
AU8424091A (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-{(3,4-dimethoxy-2-pyridyl) methylsulfinyl} benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
US5407924A (en) Method of treating pain using inositol triphosphate
EP0804242A1 (fr) Utilisation de dimeticone en tant que systeme vehiculaire et/ou d'apport medicamenteux
JP4306837B2 (ja) スクラルファート含有局所投与用医薬組成物
WO2004108110A1 (fr) Administration sublinguale de substances pharmacologiques anti-inflammatoires non steroidiennes
JP2938579B2 (ja) 消化管壁保護剤
RU2099065C1 (ru) Препарат для лечения местных осложнений консервативного противоопухолевого лечения в орофарингеальной зоне и способ лечения осложнений консервативного противоопухолевого лечения в орофарингеальной зоне
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
US20210137837A1 (en) Treatments using oxygen microbubbles and cannabidiol
EP0252033B1 (fr) Une forme galénique "gel" contenant de l'acide N-(2,6-dichloro-m-tolyl) anthranilique (acide mechlophénamique) pour utilisation dans la thérapie locale
EP0880965B1 (fr) Compositions contenant de nimesulide pour application topique
RU2147877C1 (ru) Способ лечения язв желудка и двенадцатиперстной кишки
WO2002085347A1 (fr) Agent prophylactique/therapeutique pour les maladies inflammatoires des muqueuses de la cavite buccale et autres
WO1992006684A1 (fr) Nouvelle utilisation d'enprostil
RU2020931C1 (ru) Способ получения лекарственного средства для лечения язвенной болезни желудочно-кишечного тракта млекопитающих

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95192553.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 963683

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2185883

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 132496

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV1996-3007

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1995913130

Country of ref document: EP

Ref document number: 282805

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 08716161

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV1996-3007

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1995913130

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1996-3007

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995913130

Country of ref document: EP